BRPI0923176A2 - salde hemifumarato de ácido 1-[4-[1-(4-ciclo-hexil-3 trifluorometilbenzilóxi-imino)-etil]-2etil-benzil]-azetidina-3-carboxílio. - Google Patents

salde hemifumarato de ácido 1-[4-[1-(4-ciclo-hexil-3 trifluorometilbenzilóxi-imino)-etil]-2etil-benzil]-azetidina-3-carboxílio.

Info

Publication number
BRPI0923176A2
BRPI0923176A2 BRPI0923176A BRPI0923176A BRPI0923176A2 BR PI0923176 A2 BRPI0923176 A2 BR PI0923176A2 BR PI0923176 A BRPI0923176 A BR PI0923176A BR PI0923176 A BRPI0923176 A BR PI0923176A BR PI0923176 A2 BRPI0923176 A2 BR PI0923176A2
Authority
BR
Brazil
Prior art keywords
ethyl
trifluoromethylbenzyloxy
azetidine
imino
cyclohexyl
Prior art date
Application number
BRPI0923176A
Other languages
English (en)
Inventor
Caspar Vogel
Christian Riegert
Lech Ciszewski
Marilyn De La Cruz
Michael Mutz
Piotr H Karpinki
Ricardo Schneeberger
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42236293&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0923176(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BRPI0923176A2 publication Critical patent/BRPI0923176A2/pt
Publication of BRPI0923176A8 publication Critical patent/BRPI0923176A8/pt
Publication of BRPI0923176B1 publication Critical patent/BRPI0923176B1/pt
Publication of BRPI0923176B8 publication Critical patent/BRPI0923176B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13—Dicarboxylic acids
    • C07C57/15—Fumaric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BRPI0923176A 2008-12-18 2009-12-16 forma cristalina do sal de hemifumarato de ácido 1-(4-{1-[(e)- 4-ciclo-hexil-3-trifluormetil-benzilóxi-imino]-etil}-2- etil-benzil)-azetidina-3-carboxílico e composição farmaceutica BRPI0923176B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US20305308P 2008-12-18 2008-12-18
US61/203,053 2008-12-18
PCT/US2009/068143 WO2010080409A1 (en) 2008-12-18 2009-12-16 Hemifumarate salt of 1- [4- [1- ( 4 -cyclohexyl-3 -trifluoromethyl-benzyloxyimino ) -ethyl] -2 -ethyl-benzyl] -a zetidine-3-carboxylic acid

Publications (4)

Publication Number Publication Date
BRPI0923176A2 true BRPI0923176A2 (pt) 2016-02-16
BRPI0923176A8 BRPI0923176A8 (pt) 2017-09-12
BRPI0923176B1 BRPI0923176B1 (pt) 2020-12-01
BRPI0923176B8 BRPI0923176B8 (pt) 2021-05-25

Family

ID=42236293

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0923176A BRPI0923176B8 (pt) 2008-12-18 2009-12-16 forma cristalina do sal de hemifumarato de ácido 1-(4-{1-[(e)- 4-ciclo-hexil-3-trifluormetil-benzilóxi-imino]-etil}-2- etil-benzil)-azetidina-3-carboxílico e composição farmaceutica

Country Status (36)

Country Link
US (6) US20120115840A1 (pt)
EP (2) EP2676953B1 (pt)
JP (1) JP5627597B2 (pt)
KR (5) KR20110096584A (pt)
CN (2) CN104803902A (pt)
AR (3) AR074694A1 (pt)
AU (1) AU2009335924B2 (pt)
BR (1) BRPI0923176B8 (pt)
CA (2) CA2951479A1 (pt)
CL (1) CL2011001490A1 (pt)
CO (1) CO6390104A2 (pt)
CY (2) CY1114662T1 (pt)
DK (2) DK2676953T3 (pt)
EC (1) ECSP11011210A (pt)
ES (2) ES2631203T3 (pt)
HK (1) HK1159631A1 (pt)
HR (2) HRP20131106T1 (pt)
HU (1) HUE034819T2 (pt)
IL (3) IL294514A (pt)
JO (1) JO2894B1 (pt)
LT (1) LT2676953T (pt)
MA (1) MA32961B1 (pt)
MX (1) MX2011006609A (pt)
MY (1) MY152669A (pt)
NZ (1) NZ593061A (pt)
PE (2) PE20120336A1 (pt)
PL (2) PL2676953T3 (pt)
PT (2) PT2676953T (pt)
RS (2) RS56110B1 (pt)
RU (1) RU2518114C3 (pt)
SG (1) SG171785A1 (pt)
SI (2) SI2676953T1 (pt)
TW (2) TWI500603B (pt)
UY (1) UY32330A (pt)
WO (1) WO2010080409A1 (pt)
ZA (1) ZA201103709B (pt)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112013017302B1 (pt) * 2011-01-07 2021-12-07 Novartis Ag Composição farmacêutica em fase sólida
WO2012095853A1 (en) 2011-01-10 2012-07-19 Novartis Pharma Ag Modified release formulations comprising sip receptor modulators
SG11201607894RA (en) * 2014-04-10 2016-10-28 Novartis Ag S1p modulator immediate release dosage regimen
EA201692043A1 (ru) 2014-04-10 2017-02-28 Новартис Аг Лекарственная форма иммунодепрессанта
CA2973540A1 (en) 2015-02-26 2016-09-01 Novartis Ag Treatment of autoimmune disease in a patient receiving additionally a beta-blocker
EP3400211A1 (en) 2016-01-04 2018-11-14 Auspex Pharmaceuticals, Inc. Azetidine modulators of the sphingosine 1-phosphate receptor
US11958805B2 (en) * 2017-03-09 2024-04-16 Novartis Ag Solid forms comprising an oxime ether compound, compositions and methods of use thereof
US11629124B2 (en) 2017-03-09 2023-04-18 Novartis Ag Solid forms comprising an oxime ether compound, compositions and methods of use thereof
US11390583B2 (en) 2017-09-27 2022-07-19 Dr. Reddy's Laboratories Limited Process for preparation of Siponimod, its salts and solid state forms thereof
BR112020005703A2 (pt) * 2017-09-27 2020-10-20 Novartis Ag formulação parentérica compreendendo siponimod
CA3074416A1 (en) * 2017-09-29 2019-04-04 Novartis Ag Dosing regimen of siponimod
MX2020007268A (es) * 2017-09-29 2020-08-17 Novartis Ag Regimen de dosificacion de siponimod.
WO2019144094A1 (en) 2018-01-22 2019-07-25 Teva Pharmaceuticals International Gmbh Crystalline siponimod fumaric acid and polymorphs thereof
CN110776450B (zh) * 2018-07-27 2022-09-27 广东东阳光药业有限公司 一种辛波莫德晶型及其制备方法
CN111484434A (zh) * 2019-01-29 2020-08-04 东莞市东阳光仿制药研发有限公司 一种辛波莫德晶型及其制备方法
WO2020161632A1 (en) * 2019-02-07 2020-08-13 Dr. Reddy’S Laboratories Limited Crystalline solid forms of siponimod
US20220144768A1 (en) * 2019-02-27 2022-05-12 Dr. Reddy's Laboratories Limited Solid state forms of siponimod
WO2020234423A1 (en) 2019-05-21 2020-11-26 Synthon B.V. Siponimod maleic acid and fumaric acid salt
JP2023501217A (ja) 2019-10-31 2023-01-18 イドーシア ファーマシューティカルズ リミテッド Ｃｘｃｒ７アンタゴニストのｓ１ｐ１受容体調節剤との合剤
US20230212115A1 (en) * 2020-05-29 2023-07-06 Cipla Limited Methods for the preparation of sphingosine 1-phosphate receptor modulators and solid forme thereof
EP4217341A1 (en) 2020-09-25 2023-08-02 Synthon B.V. Siponimod salts and cocrystals
CN112402610A (zh) * 2020-11-20 2021-02-26 睿阜隆(杭州)生物医药有限公司 1-磷酸鞘氨醇受体调节剂在制备治疗糖尿病的药物中的新用途
WO2022127863A1 (zh) * 2020-12-16 2022-06-23 苏州晶云药物科技股份有限公司 一种羧酸类化合物半富马酸盐的晶型及其制备方法
US20240150282A1 (en) 2021-03-26 2024-05-09 Olon S.P.A. Novel crystalline compound of siponimod hemifumarate
EP4212156A1 (en) 2022-01-13 2023-07-19 Abivax Combination of 8-chloro-n-(4-(trifluoromethoxy)phenyl)quinolin-2-amine and its derivatives with a s1p receptor modulator

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL86632A0 (en) 1987-06-15 1988-11-30 Ciba Geigy Ag Derivatives substituted at methyl-amino nitrogen
ATE124217T1 (de) * 1991-06-04 1995-07-15 Fujisawa Pharmaceutical Co Vorbeugende/therapeutische zusammensetzung für die pleuropneumonie des schweins.
NZ243082A (en) 1991-06-28 1995-02-24 Ici Plc 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof
AU661533B2 (en) 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
TW225528B (pt) 1992-04-03 1994-06-21 Ciba Geigy Ag
DK1167384T3 (da) 1992-10-28 2007-04-10 Genentech Inc Vaskular endotheliel cellevækstfaktor antagonister
ATE217204T1 (de) * 1993-06-08 2002-05-15 Hisamitsu Pharmaceutical Co Iontophoretisches system
GB9314893D0 (en) 1993-07-19 1993-09-01 Zeneca Ltd Quinazoline derivatives
US5362718A (en) 1994-04-18 1994-11-08 American Home Products Corporation Rapamycin hydroxyesters
EP2295415A1 (en) 1995-03-30 2011-03-16 OSI Pharmaceuticals, Inc. Quinazoline derivatives
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
US5747498A (en) 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
US5880141A (en) 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
HUP9900330A3 (en) 1995-07-06 2001-08-28 Novartis Ag Pyrrolopyrimidines and processes for the preparation thereof
US5760041A (en) 1996-02-05 1998-06-02 American Cyanamid Company 4-aminoquinazoline EGFR Inhibitors
GB9603095D0 (en) 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
WO1997037970A1 (fr) * 1996-04-04 1997-10-16 Sankyo Company, Limited Derives d'acide phenylalkylcarboxylique
ES2174250T5 (es) 1996-04-12 2010-04-21 Warner-Lambert Company Llc Inhibidores irreversibles de tirosina quinasas.
US5795909A (en) * 1996-05-22 1998-08-18 Neuromedica, Inc. DHA-pharmaceutical agent conjugates of taxanes
WO1997049688A1 (en) 1996-06-24 1997-12-31 Pfizer Inc. Phenylamino-substituted tricyclic derivatives for treatment of hyperproliferative diseases
EP0937082A2 (en) 1996-07-12 1999-08-25 Ariad Pharmaceuticals, Inc. Materials and method for treating or preventing pathogenic fungal infection
DE19638745C2 (de) 1996-09-11 2001-05-10 Schering Ag Monoklonale Antikörper gegen die extrazelluläre Domäne des menschlichen VEGF - Rezeptorproteins (KDR)
EP0954315A2 (en) 1996-09-13 1999-11-10 Sugen, Inc. Use of quinazoline derivatives for the manufacture of a medicament in the treatment of hyperproliferative skin disorders
EP0837063A1 (en) 1996-10-17 1998-04-22 Pfizer Inc. 4-Aminoquinazoline derivatives
CO4950519A1 (es) 1997-02-13 2000-09-01 Novartis Ag Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion
CO4940418A1 (es) 1997-07-18 2000-07-24 Novartis Ag Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
TW557297B (en) 1997-09-26 2003-10-11 Abbott Lab Rapamycin analogs having immunomodulatory activity, and pharmaceutical compositions containing same
GB9721069D0 (en) 1997-10-03 1997-12-03 Pharmacia & Upjohn Spa Polymeric derivatives of camptothecin
CA2339961C (en) 1998-08-11 2009-01-20 Novartis Ag Isoquinoline derivatives with angiogenesis inhibiting activity
GB9824579D0 (en) 1998-11-10 1999-01-06 Novartis Ag Organic compounds
UA71587C2 (uk) 1998-11-10 2004-12-15 Шерінг Акцієнгезелльшафт Аміди антранілової кислоти та їхнє застосування як лікарських засобів
IL143596A0 (en) 1998-12-22 2002-04-21 Genentech Inc Vascular endothelial cell growth factor antagonists and uses thereof
ATE329596T1 (de) 1999-03-30 2006-07-15 Novartis Pharma Gmbh Phthalazinderivate zur behandlung von entzündlicher erkrankungen
CA2433181C (en) * 2000-12-29 2005-11-22 Pfizer Limited Amlodipine hemifumarate
US7927613B2 (en) * 2002-02-15 2011-04-19 University Of South Florida Pharmaceutical co-crystal compositions
EP1482945A1 (en) * 2002-03-20 2004-12-08 Teva Pharmaceutical Industries Ltd. Crystalline forms of quetiapine hemifumarate
US6900206B2 (en) * 2002-06-20 2005-05-31 Bristol-Myers Squibb Company Indole, azaindole and related heterocyclic sulfonylureido piperazine derivatives
DE10315917A1 (de) * 2003-04-08 2004-11-18 Schwarz Pharma Ag Hochreine Basen von 3,3-Diphenylpropylaminmonoestern
MY150088A (en) * 2003-05-19 2013-11-29 Irm Llc Immunosuppressant compounds and compositions
WO2004110330A1 (en) 2003-06-13 2004-12-23 Stephen Dichiera Adjustable bed support and bed
AR051444A1 (es) * 2004-09-24 2007-01-17 Centocor Inc Proteinas derivadas de inmunoglobulina especifica de il-23p40, composiciones, epitopos, metodos y usos
AU2005309378B2 (en) * 2004-11-29 2010-02-11 Novartis Ag Dosage regimen of an S1P receptor agonist
WO2007019255A2 (en) * 2005-08-04 2007-02-15 Novartis Ag Salts of vildagliptin
GT200600350A (es) * 2005-08-09 2007-03-28 Formulaciones líquidas
US20060223820A1 (en) * 2006-03-21 2006-10-05 Chemagis Ltd. Crystalline aripiprazole salts and processes for preparation and purification thereof
GB0612721D0 (en) * 2006-06-27 2006-08-09 Novartis Ag Organic compounds
KR20090083918A (ko) * 2006-11-07 2009-08-04 노파르티스 아게 알리스키렌 헤미푸마레이트의 결정질 형태

Also Published As

Publication number Publication date
JP5627597B2 (ja) 2014-11-19
CY1119037T1 (el) 2018-01-10
ES2631203T3 (es) 2017-08-29
CY1114662T1 (el) 2016-10-05
AR121635A2 (es) 2022-06-22
EP2676953B1 (en) 2017-03-22
BRPI0923176B1 (pt) 2020-12-01
BRPI0923176A8 (pt) 2017-09-12
MX2011006609A (es) 2011-06-30
ES2436197T3 (es) 2013-12-27
IL294514A (en) 2022-09-01
MA32961B1 (fr) 2012-01-02
TW201035048A (en) 2010-10-01
UY32330A (es) 2010-07-30
KR20160064245A (ko) 2016-06-07
PE20120336A1 (es) 2012-04-30
US20210323915A1 (en) 2021-10-21
ZA201103709B (en) 2012-01-25
LT2676953T (lt) 2017-06-26
SG171785A1 (en) 2011-07-28
BRPI0923176B8 (pt) 2021-05-25
MY152669A (en) 2014-10-31
WO2010080409A1 (en) 2010-07-15
TW201509909A (zh) 2015-03-16
US20150175536A1 (en) 2015-06-25
IL253845A0 (en) 2017-09-28
JO2894B1 (en) 2015-09-15
EP2676953A1 (en) 2013-12-25
US20180118678A1 (en) 2018-05-03
AR112227A2 (es) 2019-10-02
CA2747437A1 (en) 2010-07-15
US20230357142A9 (en) 2023-11-09
HUE034819T2 (en) 2018-02-28
PE20142374A1 (es) 2015-01-30
PL2379497T3 (pl) 2014-01-31
ECSP11011210A (es) 2011-08-31
IL253845B (en) 2022-08-01
CA2951479A1 (en) 2010-07-15
US20140005162A1 (en) 2014-01-02
HRP20131106T1 (hr) 2013-12-20
DK2676953T3 (en) 2017-07-03
KR20180006492A (ko) 2018-01-17
KR101885052B1 (ko) 2018-08-02
CO6390104A2 (es) 2012-02-29
PT2379497E (pt) 2013-11-29
AU2009335924A1 (en) 2011-06-30
HK1159631A1 (pt) 2012-08-03
KR20160129915A (ko) 2016-11-09
CN102256943A (zh) 2011-11-23
RS53041B (en) 2014-04-30
EP2379497B1 (en) 2013-08-21
NZ593061A (en) 2013-08-30
JP2012512881A (ja) 2012-06-07
AU2009335924B2 (en) 2012-11-08
RS56110B1 (sr) 2017-10-31
CN104803902A (zh) 2015-07-29
TWI500603B (zh) 2015-09-21
PL2676953T3 (pl) 2017-09-29
RU2518114C2 (ru) 2014-06-10
KR20110096584A (ko) 2011-08-30
TWI591055B (zh) 2017-07-11
US20120115840A1 (en) 2012-05-10
RU2518114C3 (ru) 2021-11-24
HRP20170916T1 (hr) 2017-09-22
US20220402870A1 (en) 2022-12-22
CA2747437C (en) 2018-08-21
SI2379497T1 (sl) 2013-12-31
IL213071A0 (en) 2011-07-31
EP2379497A1 (en) 2011-10-26
SI2676953T1 (sl) 2017-07-31
DK2379497T3 (da) 2013-11-25
PT2676953T (pt) 2017-06-29
AR074694A1 (es) 2011-02-02
KR20170062554A (ko) 2017-06-07
RU2011129222A (ru) 2013-01-27
CL2011001490A1 (es) 2012-01-13

Similar Documents

Publication Publication Date Title
BRPI0923176A2 (pt) salde hemifumarato de ácido 1-[4-[1-(4-ciclo-hexil-3 trifluorometilbenzilóxi-imino)-etil]-2etil-benzil]-azetidina-3-carboxílio.
BRPI0722082A2 (pt) Ligantes para imagiologia da inervação cardíaca
GB201108086D0 (en) Financial data comparsion tool
DK2342663T3 (da) Distribueret datalagring
EP2304619A4 (en) RECOMMENDATION OF CORRELATED INFORMATION
DK2200985T3 (da) 1,3-Disubstituerede 4-(aryl--X-phenyl)-1H-pyridin-2-oner
DK2318375T3 (da) Imidazolcarboxamider
DK2246336T3 (da) Fibroseinhibitor
BRPI0908346A2 (pt) beteria
SMAP201000111A (it) Metodo di scansione.
ITMI20061974A1 (it) Anodo per elettrolisi
SMT201200063B (it) Composti 4-[2-(-fluorofenossimetil)fenil]piperidinici
GB0811503D0 (en) Document access monitoring
ZA201003031B (en) 4-[4-(2-adamantylcarbamoyl)-5-tert-butyl-pyrazol-1-yl]benzoic acid-465
AP2011005623A0 (en) Phosphodiestarase inhibitors.
GB0906974D0 (en) Horseshoe
FR2939829B1 (fr) Store type venitien.
IT1392231B1 (it) Metodo di gestione
GB0809846D0 (en) Fishing rig storage unit
CN301015239S (zh) 牙刷保存盒(医生)
ITMC20080004U1 (it) Cavalletto per prosciutto.
ITBS20080160A1 (it) Coprizoccolo per cavalli
GB0813174D0 (en) Asset monitoring system
AT504742A3 (de) Speicherzylinder
ITRM20080071A1 (it) Scatola per bobine cinematografiche.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 01/12/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 16/12/2009 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF